Key result
IV t-PA shows no benefit over DAPT for all-cause mortality in minor stroke.
Why the study?
The study was conducted to compare the outcomes between dual antiplatelet therapy and intravenous tissue plasminogen activator in patients with minor stroke.
Does intravenous tissue plasminogen activator improve functional outcomes or reduce mortality and stroke incidence compared to dual antiplatelet therapy in patients with minor stroke?
Meta-Analysis (n=2,292)
Does intravenous tissue plasminogen activator improve functional outcomes or reduce mortality and stroke incidence compared to dual antiplatelet therapy in patients with minor stroke?
Relative Risk: 1.14 (95% CI 0.32–4.06)
In patients with minor stroke, intravenous t-PA does not significantly improve 90-day functional outcomes, mortality, or stroke recurrence compared to dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
May support DAPT as alternative in minor stroke; confirms no tPA mortality benefit and extends null findings.
Monday et al. (2023) conducted a meta-analysis in Minor stroke (n=2,292). Intravenous tissue plasminogen activator vs. Dual antiplatelet therapy was evaluated on All-cause mortality (RR 1.14, 95% CI 0.32-4.06). Intravenous tissue plasminogen activator showed no significant difference compared to dual antiplatelet therapy regarding all-cause mortality (RR 1.14) in patients with minor stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: